

**IN THE CLAIMS**

1-14 (canceled)

15 (currently amended) A method for the treatment of infections by Herpesviridae and/or skin tumors in a subject comprising administering to the subject in need thereof an active amount of at least 0.1 mg of xenogeneic oligo- and/or polyribonucleotides ~~per unit dose~~ once per recurrence of symptoms.

16-18 (cancel)

19. (currently amended) A method for treating lesions of the skin and/or mucosa caused by *Herpes simplex* virus and/or *Varicella zoster* virus comprising administering a therapeutically effective amount of a ~~of the~~ pharmaceutical composition comprising xenogenic oligo- and/or polyribonucleotides to a subject in need thereof once per recurrence of symptoms.

20. (currently amended) A method for the treatment of infections by Herpesviridae and/or skin tumors, comprising administering an active amount of at least 0.1 mg of xenogeneic oligo- and/or polyribonucleotides in an anhydrous preparation ~~per dose unit is administered~~ once per recurrence of symptoms to a ~~to the~~ subject in need thereof.

21. (currently amended) A method for the treatment of infections by at least one of Herpesviridae or skin tumors comprising administering to a subject in need thereof a therapeutically effective amount of ~~xenophobic xenophic~~ oligo- and/or polyribonucleotides once per recurrence of symptoms.

22. (currently amended) The method of claim 21, wherein the therapeutically effective amount ~~is at~~ is at ~~of at~~ least 0.1 mg.

23. (previously presented) The method of claim 15, wherein said oligo- and/or polyribonucleotides are administered topically.
24. (previously presented) The method of claim 23, wherein said oligo- and/or polyribonucleotides are a powder.
25. (previously presented) The method of claim 19, wherein said oligo- and/or polyribonucleotides are administered topically.
26. (previously presented) The method of claim 25, wherein said oligo- and/or polyribonucleotides are a powder.
27. (previously presented) The method of claim 20, wherein said oligo- and/or polyribonucleotides are administered topically.
28. (previously presented) The method of claim 27, wherein said oligo- and/or polyribonucleotides are a powder.
29. (currently amended) The method of claim 15, wherein said xenogenic oligo- and/or polyribonucleotides are obtained ~~directly~~ from a plant, an animal or a unicellular organism.
30. (currently amended) The method of claim 19, wherein said xenogenic oligo- and/or polyribonucleotides are obtained ~~directly~~ from a plant, an animal or a unicellular organism.
31. (currently amended) The method of claim 20, wherein said xenogenic oligo- and/or polyribonucleotides are obtained ~~directly~~ from a plant, an animal or a unicellular organism.
32. (previously presented) The method of claim 29, wherein said oligo- and/or polyribonucleotides are administered topically.
33. (previously presented) The method of claim 29, wherein said oligo- and/or polyribonucleotides are a powder.

34. (previously presented) The method of claim 30, wherein said oligo- and/or polyribonucleotides are administered topically.
35. (previously presented) The method of claim 30, wherein said oligo- and/or polyribonucleotides are a powder.
36. (previously presented) The method of claim 31, wherein said oligo- and/or polyribonucleotides are administered topically.
37. (previously presented) The method of claim 31, wherein said oligo- and/or polyribonucleotides are a powder.